Multimodality Imaging in Contemporary Cardio-Oncology: Beyond Ejection Fraction.
Authors
Affiliations (17)
Affiliations (17)
- U.O.C. Cardiologia "Unità Coronarica e Emodinamica", Ospedale Madonna delle Grazie, 81740 Matera, Italy.
- S.C. Cardiologia 4-Diagnostica e Riabilitativa, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milano, Italy.
- Azienda Ospedaliera Villa Sofia Cervello, UOC Cardiologia Presidio Cervello, 90146 Palermo, Italy.
- UOSD Cardiologia di Interesse Oncologico, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy.
- UOC Cardiologia e UTIC, Ospedale Guglielmo da Saliceto di Piacenza, 29121 Piacenza, Italy.
- UOC Cardiologia, Ospedale Versilia, Azienda USL Toscana Nord Ovest, 55041 Toscana, Italy.
- Cardiology and Arrhythmology Clinic, Polytechnic University of Ancona, 60126 Ancona, Italy.
- Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy.
- Dipartimento Cardiotoracico, Fondazione Toscana Gabriele Monasterio, 56124 Pisa, Italy.
- Dipartimento di Cardiologia, Arcispedale Santa Maria Nuova, AUSL Reggio Emilia-IRCCS, 42123 Reggio Emilia, Italy.
- Department of Clinical Science and Education, Karolinska Institutet, SE-118 83 Stockholm, Sweden.
- Cardiology Department, Santa Maria delle Grazie Hospital, 80078 Naples, Italy.
- Unità di Cure Intensive Cardiologiche, Cardiologia 1-Emodinamica, Dipartimento Cardiotoracovascolare "A. De Gasperis", ASST Grande Ospedale Metropolitano Niguarda, 20162 Milano, Italy.
- Dipartimento di Cardiologia, Ospedale Santo Spirito, Casale Monferrato, 15033 Alessandria, Italy.
- U.O.C. Cardiologia-UTIC, Ospedale Miulli, Acquaviva delle Fonti, 70021 Bari, Italy.
- ANMCO-Associazione Nazionale Medici Cardiologi Ospedalieri, 50121 Firenze, Italy.
- HCF Fondazione ANMCO per il tuo Cuore ETS, 50121 Firenze, Italy.
Abstract
<b>Background</b>: Cancer therapy-related cardiac dysfunction (CTRCD) may develop before symptoms or a measurable decline in left ventricular ejection fraction (LVEF). Surveillance therefore requires assessment beyond LVEF alone. <b>Content</b>: This narrative review examines cardiotoxic mechanisms, imaging findings, and treatment-specific surveillance. Transthoracic echocardiography with LVEF and global longitudinal strain remains the first-line approach. Myocardial work may provide additional information, but oncology-specific action thresholds remain unvalidated. Cardiac magnetic resonance complements echocardiography when measurements are inconclusive or tissue characterization is required. Mapping abnormalities are nonspecific and do not independently establish treatment-related injury. Nuclear imaging addresses selected diagnostic questions; fibroblast activation protein inhibitor PET remains investigational. Artificial intelligence may support image analysis and data integration, although evidence from general cardiovascular populations requires oncology-specific validation. An algorithm and surveillance matrix link clinical findings, treatment, baseline risk, imaging, and biomarkers. <b>Conclusions</b>: A tiered approach organizes surveillance around specific clinical questions. Earlier detection should be distinguished from demonstrated clinical benefit: evidence that imaging-guided strategies improve long-term cardiovascular outcomes remains limited. Prospective studies are needed to validate emerging markers, AI applications, and the clinical and economic effects of integrated surveillance pathways.